Developer docs
API playgroundTry for free, no card

Search company profiles

Torigen Pharmaceuticals

Full company profile

uuid0000ojy

Namestring
Torigen Pharmaceuticals
Legal namestring
Torigen, Inc.
Websiteurl
torigen.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Torigen Pharmaceuticals is a Farmington, Connecticut-based veterinary oncology company founded in 2013 that operates a vertically integrated platform spanning cancer diagnostics and personalized immunotherapy for companion animals. The company's core technology combines Torigen Specialty Pathology (TSP), a diagnostic service that delivers expert pathological evaluations with 3-6 day turnaround, with VimClara, described as the first-ever autologous cancer vaccine kit designed to produce personalized cancer vaccines from a patient's own tumor tissue. Supporting products include the free TSP Kit for formalin-fixed tissue histopathology and the free Tumor Collection Kit (TCK) for fresh tissue submission that preserves the option for downstream VimClara immunotherapy production.

The company employs a freemium-led, channel-driven go-to-market model. Tumor Collection Kits and TSP Kits are provided at no charge to veterinary clinics, lowering the adoption barrier and embedding Torigen into the clinic workflow at the point of biopsy. Revenue is generated when clinics progress to VimClara immunotherapy production, with pricing not publicly disclosed. Customer acquisition runs primarily through veterinary clinic partnerships, supported by preferred distribution agreements with VerticalVet and Veterinary Management Groups that extend reach into affiliated clinic networks, and supplemented by direct inquiries from pet owners. The company also operates a dedicated clinic portal (torigen.vet) for order management and case tracking.

Torigen is a venture-backed private company that has raised approximately $16.1 million across multiple rounds, most notably a $13 million Series A1 in November 2022 co-led by Werth Family Investment Associates and Connecticut Innovations. The company is led by co-founder and CEO Ashley Kalinauskas, with Mark Suckow as co-founder and CTO and John Kallassy as CFO. Current operations are domestic, with primary geographic concentration in Connecticut and surrounding markets served through partner clinic networks.

Short descriptiontext

Torigen Pharmaceuticals is a veterinary oncology company offering cancer diagnostics and personalized autologous immunotherapy vaccines for companion animals, serving veterinary clinics and pet owners primarily in the United States.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersFarmington, United States
HQ citystring
Farmington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
veterinary oncology products, autologous cancer vaccines, veterinary pathology services, pet cancer immunotherapy, animal health diagnostics
Industry3 codes
PRIMARYHLAMAKAA
Companion Animal Vaccines (Dogs & Cats)
SECONDARYHLAMAKAH
Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA)
SECONDARYAFAEANAK
Veterinary Pharmacy, Vaccine & Biologics Services
NAICS code4 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • Veterinary Services54194
  • Medical Laboratories621511
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
  • Services-Medical Laboratories8071
Product category
Veterinary Oncology Pharmaceuticals
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Immunotherapy Products and Services
TypeOne Time License
Description

Torigen generates revenue through the sale of personalized cancer immunotherapies and diagnostic services for veterinary patients. The VimClara kit enables veterinarians to produce personalized vaccines, while TSP provides pathology diagnostic services.

torigen.com
2Specialty Pathology Diagnostics
TypeProfessional Services
Description

Provides cancer diagnostic services to veterinary clinics through Torigen Specialty Pathology, offering expert pathological evaluations with rapid turnaround times.

torigen.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure
Pricing details1 tier
1Free tumor submission kits for veterinary clinics
ModelFreemiumBilling cadencePay-as-you-go
Notes

TSP Kits for formalin-fixed tissue histopathology are free of charge. Tumor Collection Kits (TCKs) for fresh tissue submission are also free. These free kits enable histopathology and preserve the option for immunotherapy.

torigen.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Torigen Specialty Pathology (TSP)
Description

Specialty pathology service combining speed, expertise, and accessibility for comprehensive cancer diagnostics in veterinary patients, offering 3-6 day turnaround time with expert pathologist analysis

torigen.com
+1 more record
Core offering1 text field

Torigen Pharmaceuticals develops and commercializes veterinary oncology products and services, anchored by VimClara, the first-ever autologous cancer vaccine kit that enables veterinarians to manufacture personalized cancer vaccines from a patient's own tumor tissue, and Torigen Specialty Pathology (TSP), which provides expert cancer diagnostic evaluations with a 3-6 day turnaround. Free Tumor Collection Kits (TCK) and TSP Kits funnel samples from veterinary clinics into the platform. The company serves veterinary clinics and pet owners seeking advanced cancer treatment options for companion animals.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • 3-6 day turnaround time for cancer diagnostic reports
Product overview1 text field

Torigen Pharmaceuticals offers a unified veterinary oncology platform combining comprehensive cancer diagnostics and individualized immunotherapy. The portfolio centers on Torigen Specialty Pathology (TSP) for expert pathological evaluations and VimClara, the first-ever autologous cancer vaccine kit that produces personalized cancer vaccines from a patient's own tumor tissue. Supporting products include the TSP Kit for formalin-fixed tissue histopathology and the Tumor Collection Kit (TCK) for fresh tissue submission with immunotherapy option preservation.

Product and service4 records
1VimClara
CategoryVeterinary cancer immunotherapy product
Description

The first-ever autologous cancer vaccine kit intended for the production of a personalized cancer vaccine from a patient's own tumor tissue, enabling veterinary clinics to offer advanced targeted immunotherapy to their cancer patients.

2Torigen Specialty Pathology (TSP)
CategoryVeterinary pathology diagnostic service
Description

Comprehensive cancer diagnostics service that delivers fast, reliable pathological evaluations with a 3-6 day turnaround time from specialized pathologists, accessible to veterinary practices of all sizes. Sending tumor samples to TSP also opens the door to VimClara immunotherapy.

3TSP Kit
CategorySample collection / diagnostic sub-product
Description

Free sample-submission kit for veterinarians to send formalin-fixed tissue to Torigen Specialty Pathology for histopathology-only cases; these cases are not used for immunotherapy.

4Tumor Collection Kit (TCK)
CategorySample collection / immunotherapy sub-product
Description

Free kit for submitting fresh (non-formalin) tumor tissue to Torigen for histopathology, with a representative sample preserved to enable VimClara immunotherapy if requested after diagnosis.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMajorTypeGTM or Marketing PartnerAnnounced on2023-04-01
Description

Entered into a preferred partner agreement to provide cancer diagnostics and immunotherapy services to their network of affiliated veterinary practices. This partnership expands market access through established veterinary clinic networks.

Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-12-01
Description

Entered into a preferred partnership to distribute Torigen's specialty pathology and immunotherapy services through VerticalVet's veterinary clinic network. Enables broader market reach through existing distribution channels.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

ELIAS Animal Health develops immunotherapies for veterinary cancer patients, including autologous cancer vaccines. It is the closest direct competitor to Torigen's VimClara platform in the pet autologous immunotherapy category.

TypeBroad incumbent
Description

Zoetis is the largest global animal health company with a broad portfolio of veterinary pharmaceuticals, vaccines, and diagnostics. It serves as the incumbent comparator in the broader veterinary oncology and animal biologics market where Torigen competes.

TypeBroad incumbent
Description

IDEXX is a leading veterinary diagnostics company offering in-clinic lab testing and reference lab services. It is comparable to Torigen's TSP diagnostic offering and represents the diagnostic incumbent in the veterinary oncology workflow.

TypeBroad incumbent
Description

Antech Diagnostics, part of Mars Petcare, provides veterinary reference laboratory and imaging services across North America. It competes with Torigen Specialty Pathology in cancer diagnostic services for veterinary clinics.

TypeEmerging player
Description

PetCure Oncology operates a network of veterinary radiation oncology clinics. It is an emerging player in the broader pet cancer treatment market and represents an alternative treatment modality that competes for clinic referrals.

TypeBroad incumbent
Description

Virbac is a global animal health company with a portfolio of veterinary pharmaceuticals, vaccines, and specialty products. Comparable to Torigen as a broader veterinary biologics and specialty therapeutics player.

7VetDC
TypeEmerging player
Description

VetDC develops and commercializes novel therapeutics for veterinary cancer patients. It is an emerging specialty oncology player targeting similar veterinary clinics and pet owners as Torigen.

TypeBroad incumbent
Description

Heska (now part of Antech/Mars Petcare) sells in-clinic diagnostics, specialty veterinary products, and vaccines. Comparable to Torigen's integrated diagnostics-plus-treatment go-to-market in companion animal practices.

9Ethos Veterinary Health
TypeEmerging player
Description

Ethos operates a network of specialty and emergency veterinary hospitals including oncology services. Comparable as a channel partner and customer base for Torigen's oncology offerings.

TypeEmerging player
Description

BluePearl operates specialty veterinary hospitals including oncology services and is a potential clinic partner and customer for Torigen's VimClara and TSP offerings.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Torigen Pharmaceuticals

Veterinary Oncology Pharmaceuticalstorigen.com

Torigen Pharmaceuticals is a veterinary oncology company offering cancer diagnostics and personalized autologous immunotherapy vaccines for companion animals, serving veterinary clinics and pet owners primarily in the United States.

What Torigen Pharmaceuticals does

Torigen Pharmaceuticals is a Farmington, Connecticut-based veterinary oncology company founded in 2013 that operates a vertically integrated platform spanning cancer diagnostics and personalized immunotherapy for companion animals. The company's core technology combines Torigen Specialty Pathology (TSP), a diagnostic service that delivers expert pathological evaluations with 3-6 day turnaround, with VimClara, described as the first-ever autologous cancer vaccine kit designed to produce personalized cancer vaccines from a patient's own tumor tissue. Supporting products include the free TSP Kit for formalin-fixed tissue histopathology and the free Tumor Collection Kit (TCK) for fresh tissue submission that preserves the option for downstream VimClara immunotherapy production.

The company employs a freemium-led, channel-driven go-to-market model. Tumor Collection Kits and TSP Kits are provided at no charge to veterinary clinics, lowering the adoption barrier and embedding Torigen into the clinic workflow at the point of biopsy. Revenue is generated when clinics progress to VimClara immunotherapy production, with pricing not publicly disclosed. Customer acquisition runs primarily through veterinary clinic partnerships, supported by preferred distribution agreements with VerticalVet and Veterinary Management Groups that extend reach into affiliated clinic networks, and supplemented by direct inquiries from pet owners. The company also operates a dedicated clinic portal (torigen.vet) for order management and case tracking.

Torigen is a venture-backed private company that has raised approximately $16.1 million across multiple rounds, most notably a $13 million Series A1 in November 2022 co-led by Werth Family Investment Associates and Connecticut Innovations. The company is led by co-founder and CEO Ashley Kalinauskas, with Mark Suckow as co-founder and CTO and John Kallassy as CFO. Current operations are domestic, with primary geographic concentration in Connecticut and surrounding markets served through partner clinic networks.

Torigen Pharmaceuticals firmographics

Firmographics
Name
Torigen Pharmaceuticals
Legal name
Torigen, Inc.
Website
https://torigen.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
Torigen Pharmaceuticals is a veterinary oncology company offering cancer diagnostics and personalized autologous immunotherapy vaccines for companion animals, serving veterinary clinics and pet owners primarily in the United States.
Ownership category
akta.pro rank

Torigen Pharmaceuticals industry classification

Industry
Product category
Veterinary Oncology Pharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Veterinary Services (54194), Medical Laboratories (621511)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAMAKAA
Companion Animal Vaccines (Dogs & Cats)
SECONDARYHLAMAKAH
Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA)
SECONDARYAFAEANAK
Veterinary Pharmacy, Vaccine & Biologics Services

Keywords

  • Veterinary oncology products
  • Autologous cancer vaccines
  • Veterinary pathology services
  • Pet cancer immunotherapy
  • Animal health diagnostics

Where Torigen Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Farmington
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Torigen Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Immunotherapy Products and Services: Torigen generates revenue through the sale of personalized cancer immunotherapies and diagnostic services for veterinary patients. The VimClara kit enables veterinarians to produce personalized vaccines, while TSP provides pathology diagnostic services.
  2. Specialty Pathology Diagnostics: Provides cancer diagnostic services to veterinary clinics through Torigen Specialty Pathology, offering expert pathological evaluations with rapid turnaround times.

Pricing tiers

ModelBillingPrice
FreemiumPay-as-you-goFree tumor submission kits for veterinary clinics

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Torigen Pharmaceuticals product offering

Product offering

Core offering

Torigen Pharmaceuticals develops and commercializes veterinary oncology products and services, anchored by VimClara, the first-ever autologous cancer vaccine kit that enables veterinarians to manufacture personalized cancer vaccines from a patient's own tumor tissue, and Torigen Specialty Pathology (TSP), which provides expert cancer diagnostic evaluations with a 3-6 day turnaround. Free Tumor Collection Kits (TCK) and TSP Kits funnel samples from veterinary clinics into the platform. The company serves veterinary clinics and pet owners seeking advanced cancer treatment options for companion animals.

Product overview

Torigen Pharmaceuticals offers a unified veterinary oncology platform combining comprehensive cancer diagnostics and individualized immunotherapy. The portfolio centers on Torigen Specialty Pathology (TSP) for expert pathological evaluations and VimClara, the first-ever autologous cancer vaccine kit that produces personalized cancer vaccines from a patient's own tumor tissue. Supporting products include the TSP Kit for formalin-fixed tissue histopathology and the Tumor Collection Kit (TCK) for fresh tissue submission with immunotherapy option preservation.

Differentiator

Problem solved

Functional benefit

Brands

  • Torigen Specialty Pathology (TSP): Specialty pathology service combining speed, expertise, and accessibility for comprehensive cancer diagnostics in veterinary patients, offering 3-6 day turnaround time with expert pathologist analysis
  • VimClara

Products and services

  • VimClara The first-ever autologous cancer vaccine kit intended for the production of a personalized cancer vaccine from a patient's own tumor tissue, enabling veterinary clinics to offer advanced targeted immunotherapy to their cancer patients.
  • Torigen Specialty Pathology (TSP) Comprehensive cancer diagnostics service that delivers fast, reliable pathological evaluations with a 3-6 day turnaround time from specialized pathologists, accessible to veterinary practices of all sizes. Sending tumor samples to TSP also opens the door to VimClara immunotherapy.
  • TSP Kit Free sample-submission kit for veterinarians to send formalin-fixed tissue to Torigen Specialty Pathology for histopathology-only cases; these cases are not used for immunotherapy.
  • Tumor Collection Kit (TCK) Free kit for submitting fresh (non-formalin) tumor tissue to Torigen for histopathology, with a representative sample preserved to enable VimClara immunotherapy if requested after diagnosis.

Quantifiable outcome

  • 3-6 day turnaround time for cancer diagnostic reports

Companies that use Torigen Pharmaceuticals

Customer profile

Segments2 records

Ideal customer profiles2 records

Torigen Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Torigen Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered major.

  • Veterinary Management GroupsmajorGTM or Marketing Partner · 1 April 2023Entered into a preferred partner agreement to provide cancer diagnostics and immunotherapy services to their network of affiliated veterinary practices. This partnership expands market access through established veterinary clinic networks.
  • VerticalVetmajorChannel Partner/ Reseller/ Distributor · 1 December 2022Entered into a preferred partnership to distribute Torigen's specialty pathology and immunotherapy services through VerticalVet's veterinary clinic network. Enables broader market reach through existing distribution channels.

Scale indicators3 records

Recent moves7 records

Expansion highlights4 records

Torigen Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • ELIAS Animal Health: ELIAS Animal Health develops immunotherapies for veterinary cancer patients, including autologous cancer vaccines. It is the closest direct competitor to Torigen's VimClara platform in the pet autologous immunotherapy category.

Broad incumbents

  • Zoetis: Zoetis is the largest global animal health company with a broad portfolio of veterinary pharmaceuticals, vaccines, and diagnostics. It serves as the incumbent comparator in the broader veterinary oncology and animal biologics market where Torigen competes.
  • IDEXX Laboratories: IDEXX is a leading veterinary diagnostics company offering in-clinic lab testing and reference lab services. It is comparable to Torigen's TSP diagnostic offering and represents the diagnostic incumbent in the veterinary oncology workflow.
  • Antech Diagnostics: Antech Diagnostics, part of Mars Petcare, provides veterinary reference laboratory and imaging services across North America. It competes with Torigen Specialty Pathology in cancer diagnostic services for veterinary clinics.
  • Virbac: Virbac is a global animal health company with a portfolio of veterinary pharmaceuticals, vaccines, and specialty products. Comparable to Torigen as a broader veterinary biologics and specialty therapeutics player.
  • Heska Corporation: Heska (now part of Antech/Mars Petcare) sells in-clinic diagnostics, specialty veterinary products, and vaccines. Comparable to Torigen's integrated diagnostics-plus-treatment go-to-market in companion animal practices.

Emerging players

  • PetCure Oncology: PetCure Oncology operates a network of veterinary radiation oncology clinics. It is an emerging player in the broader pet cancer treatment market and represents an alternative treatment modality that competes for clinic referrals.
  • VetDC: VetDC develops and commercializes novel therapeutics for veterinary cancer patients. It is an emerging specialty oncology player targeting similar veterinary clinics and pet owners as Torigen.
  • Ethos Veterinary Health: Ethos operates a network of specialty and emergency veterinary hospitals including oncology services. Comparable as a channel partner and customer base for Torigen's oncology offerings.
  • BluePearl Specialty and Emergency Pet Hospital: BluePearl operates specialty veterinary hospitals including oncology services and is a potential clinic partner and customer for Torigen's VimClara and TSP offerings.

Market position

Strengths1 record

Competitive moat3 records

Key highlights7 records

Customer concentration

Torigen Pharmaceuticals social profiles

Digital presence

Torigen Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Torigen Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles3 records

Torigen Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Torigen Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Torigen Pharmaceuticals

What does Torigen Pharmaceuticals do?

Torigen Pharmaceuticals develops and commercializes veterinary oncology products and services, anchored by VimClara, the first-ever autologous cancer vaccine kit that enables veterinarians to manufacture personalized cancer vaccines from a patient's own tumor tissue, and Torigen Specialty Pathology (TSP), which provides expert cancer diagnostic evaluations with a 3-6 day turnaround. Free Tumor Collection Kits (TCK) and TSP Kits funnel samples from veterinary clinics into the platform. The company serves veterinary clinics and pet owners seeking advanced cancer treatment options for companion animals.

Is Torigen Pharmaceuticals a public or private company?

Torigen Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.

When was Torigen Pharmaceuticals founded?

Torigen Pharmaceuticals was founded in 2013. It employs 11 to 50 people.

Where is Torigen Pharmaceuticals based?

Torigen Pharmaceuticals is headquartered in Farmington, United States, in the North America region.

How does Torigen Pharmaceuticals make money?

Two revenue lines are on record. Immunotherapy Products and Services are the primary driver. The others are specialty Pathology Diagnostics.

Who are Torigen Pharmaceuticals's main competitors?

ELIAS Animal Health is listed as a direct peer. Broad incumbents are Zoetis, IDEXX Laboratories, Antech Diagnostics, Virbac and Heska Corporation. Emerging players are PetCure Oncology, VetDC, Ethos Veterinary Health and BluePearl Specialty and Emergency Pet Hospital.

Does Torigen Pharmaceuticals have an API?

No public API is recorded for Torigen Pharmaceuticals.

What industry is Torigen Pharmaceuticals in?

Torigen Pharmaceuticals's product category is Veterinary Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAMAKAA, Companion Animal Vaccines (Dogs & Cats), with a secondary code of HLAMAKAH, Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
DVM 360Novel Cancer Vaccine Uses Animal's Own Tumor CellsTorigen Pharmaceuticals has developed and commercialized a personalized autologous cancer vaccine for dogs and cats that utilizes the patient's own deactivated tumor cells to stimulate an immune response. The company reports that approximately 250 vaccines have been created since 2017, with clinical data showing low adverse event rates and efficacy in treating various solid tumors. Torigen is currently seeking major investments to expand its operations and establish itself as a leader in canine oncology.RdworldonlineChatGPT, mRNA and a dog named Rosie: Torigen CEO on what the viral cancer story reveals about pet immunotherapyFollowing the viral story of an AI-designed mRNA vaccine for a dog named Rosie, veterinary immunotherapy company Torigen clarified the distinction between its autologous whole-cell therapy and emerging mRNA approaches. Torigen CEO Ashley Kalinauskas highlighted the regulatory complexities, early-stage clinical evidence, and technical challenges inherent in personalized pet cancer treatments compared to human drug development.UConn TodayCAHNR Alum Ashley Kalinauskas Helps Pets Fight CancerTorigen Pharmaceuticals, led by CEO Ashley Kalinauskas, provides a personalized cancer vaccine for pets and other animals that utilizes the patient's own tumor cells to boost immune response. The company operates in the U.S., offering diagnostic and consulting services alongside its treatment kits, with plans to expand globally.GlobeNewswireNew Hope For Pets In The Fight Against Cancer: Fast, Accurate Diagnoses From Torigen Pharmaceuticals And ProsciaTorigen Pharmaceuticals is using Proscia's Concentriq platform to deliver rapid pathology diagnoses for pet cancer, aiming to inform personalized vaccines. Preliminary data shows dogs with metastatic hemangiosarcoma receiving Torigen's immunotherapy had a 3.5x increase in overall survival compared to surgery alone. The company is also building AI models to optimize immunotherapy recommendations.PatchFarmington Company Gives Gift Of Time To Beloved PetsTorigen Pharmaceuticals Inc. has officially opened a new 7,800-square-foot production facility and headquarters in Farmington, Connecticut, to expand its capacity for producing immuno-therapeutics for companion animals. The company specializes in developing cancer treatments for dogs, cats, and horses, aiming to extend the lives of pets through affordable medical solutions.College of ScienceThree Notre Dame alumni who are changing the world – powered by ESTEEMThree graduates of the University of Notre Dame's ESTEEM program have successfully founded and scaled biotech and technology companies: Ochre Bio, Torigen Pharmaceuticals, and Flagship Management Inc. Each company has secured significant funding, with Ochre Bio raising $30 million and Torigen completing a $13 million round, while Flagship Management has expanded its customer base including ATI Physical Therapy.BitlyTorigen Pharmaceuticals Closes $13M Series A1 FundingTorigen Pharmaceuticals, a Farmington-based animal health company, closed a $13 million Series A1 funding round. The investment was led by Werth Family Investment Associates and Connecticut Innovations, with participation from several other venture firms and university funds. Torigen plans to utilize the capital to develop new pet cancer immunotherapies and expand its salesforce.PR NewswireInstantGMP Inc. enters new territory with latest client Torigen PharmaceuticalsInstantGMP Inc. has added Torigen Pharmaceuticals as a client, expanding its software solutions into the veterinary biologics industry. This partnership marks a strategic expansion for InstantGMP, which provides all-in-one manufacturing and quality systems.FinSMEsTorigen Pharmaceuticals Closes $13M Series A1 Funding RoundTorigen Pharmaceuticals, a Connecticut-based animal health biologics company, raised $13 million in a Series A1 funding round led by Werth Family Investment Associates and Connecticut Innovations. The company plans to use the funds to develop new products and grow its sales team.Venture Capital Access OnlineTorigen Pharmaceuticals Announces Completion of $13 Million Capital RaiseTorigen Pharmaceuticals announced the completion of a $13 million Series A1 capital raise led by Werth Family Investment Associates and Connecticut Innovations, bringing its total funding to $18 million. The company intends to use these funds to expand its platform for personalized cancer immunotherapies for pets and is currently recruiting a skilled salesforce to meet market demand.